Initial therapy of multiple myeloma with lenalidomide-based regimens can compromise stem cell collection, which can be overcome with the addition of plerixafor. Plerixafor is typically given subcutaneously (SQ), with collection B11 h later for maximum yield. Intravenous administration may allow more rapid and predictable mobilization. This trial was designed to assess the efficacy and feasibility of IV plerixafor in patients receiving initial therapy with a lenalidomide-based regimen. Patients received G-CSF at 10 mg/kg/day for 4 days followed by IV plerixafor at 0.24 mg/kg/dose starting on day 5; plerixafor was administered early in the morning with apheresis 4-5 h later. Thirty-eight (97%) patients collected at least 3 Â 10 6 CD34 þ cells/kg within 2 days of apheresis. The median CD34 þ cells/kg after 1 day of collection was 3.9 Â 10 6 (range: 0.7-9.2) and after 2 days of collection was 6.99 Â 10 6 (range: 1.1-16.5). There were no grade 3 or 4 non-hematological adverse events, and one patient experienced grade 4 thrombocytopenia. The most common adverse events were nausea, diarrhea and abdominal bloating. IV plerixafor is an effective strategy for mobilization with low failure rate and is well tolerated. It offers flexibility with a schedule of early-morning infusion followed by apheresis later in the day.
INTRODUCTION
Auto-SCT remains an integral part of the current management of multiple myeloma in transplant-eligible patients. [1] [2] [3] Traditionally, patients undergo 4-6 months of initial therapy with one of several commonly used regimens followed by PBSC mobilization. Following a successful stem cell harvest, patients either proceed to an immediate auto-SCT or continue with the initial therapy and use auto-SCT at the time of relapse. 4 One of the critical steps in this process remains the ability to collect an adequate number of stem cells for a successful auto-SCT. Nearly 10% of patients may fail to yield the minimum number of stem cells required for the auto-SCT, depending on the mobilization process utilized. [5] [6] [7] In addition, the initial therapy employed for myeloma management also has significant impact on the success of stem cell mobilization. [8] [9] [10] [11] [12] Whereas alkylating agents that can impair stem cell mobilization are rarely used currently as part of initial therapy in transplant-eligible patients, newer drugs such as lenalidomide can also impair the collection process. [11] [12] [13] [14] The most common approaches to stem cell mobilization until recently have been the use of G-CSF alone or G-CSF following pulse dose chemotherapy. 5 The chemotherapy approach has lower failure rates but is associated with increased risk of neutropenic fever and consequent complications. More recently, the introduction of plerixafor, a CXCR4 antagonist, has radically changed stem cell mobilization, considerably reducing the rate of mobilization failures when used in conjunction with G-CSF. [15] [16] [17] [18] [19] Risk-adapted strategies for the use of plerixafor based on circulating CD34 þ cell numbers or apheresis yields have allowed us to successfully mobilize and collect stem cells in nearly all patients and provide the opportunity to proceed with a SCT when recommended. 18, [20] [21] [22] [23] [24] [25] However, the current schedule for plerixafor administration late in the evening prior to collection and the relatively narrow window for collecting the stem cells introduce logistical difficulties. 26 Whereas the majority of the studies have used plerixafor by the SQ route, and the current label indicates SQ route, i.v. administration has been studied in a limited manner. Following SQ administration, plerixafor is absorbed rapidly with 70-80% bioavailability in healthy volunteer studies. Estimates of C max and area under the curve were higher following IV administration compared with SQ dosing, whereas terminal half-lives were comparable between the two routes. In the healthy volunteer studies, the peak peripheral blood CD34 þ cell counts were seen 10-14 h after administration of plerixafor, leading to the current recommendations of injection and apheresis schedules. We designed this trial with the following two objectives: (1) to determine the risk of failure of stem cell mobilization with plerixafor and G-CSF among patients receiving a lenalidomidebased induction therapy for myeloma and (2) to determine the safety and efficacy of i.v. administered plerixafor in the setting of patients with myeloma undergoing PBSC mobilization. 
SUBJECTS AND METHODS Patients
Patients with a diagnosis of symptomatic multiple myeloma receiving initial treatment with a lenalidomide-based treatment regimen started p12 months prior to registration were enrolled. Patients should have received at least two cycles of treatment with the lenalidomide regimen with the last dose of lenalidomide 42 weeks prior to registration, and patients should be eligible for and be considered for SCT. The trial was approved by the Mayo Foundation Institutional Review Board and was carried out in accordance with the Helsinki Principle. The clinical trial was registered at www.clinicaltrials.gov as NCT00998049.
The objectives of the trial were to determine the proportion of patients reaching a stem cell yield of 3 Â 10 6 CD34 þ cells/kg by the second day of apheresis with intravenously administered plerixafor, the safety and tolerability of intravenously administered plerixafor and the overall rate of failure to mobilize minimum required number of stem cells for an Auto-SCT (o2.5 Â 10 6 CD34 þ cells/kg). Toxicities were graded using CTCAE v 4.0 (Genzyme Corporation, Cambridge, MA, USA). Adverse event assessment was performed daily during the study.
Treatment
Patients received G-CSF (10 mg/kg), daily SQ injection beginning Day 1, once they completed the required pre-transplant evaluation. On the morning of day 5 of G-CSF administration, plerixafor was administered at a dose of 240 mcg/kg (160 mcg/kg if CrClo30 mL/min) intravenously. The same formulation as that used for SQ administration was used but diluted in a larger volume. The dose to be administered was added to 50 mL of normal saline. The drug was administered using standard infusion tubing via slow infusion over 30 min. At the end of the infusion, the line was flushed with 10 mL of normal saline. Patients then proceeded to large volume leukapheresis on the Fenwal Amicus (Fenwal Inc, Lake Zurich, IL, USA) utilizing version 2.5 software. The collection method has previously been described. 27 In brief, patients underwent leukapheresis for 5 h with patients with WBC counts of o35 Â 10 9 /L processed at a blood flow rate of 90 mL/min utilizing a cycle volume of 1400 mL and those with WBC counts 435 Â 10 9 /L processed at a blood flow rate of 65 mL/min utilizing a cycle volume of 1000 mL. 28 Anticoagulant consisted of a mixture of ACD-A (Baxter Healthcare Corp, Deerfield, IL, USA), normal saline and heparin. The citrate infusion rate was 2.50 mg/kg/min and anticoagulant ratio was 13:1. MNC offset was 1.5 mL and RBC offset was 5 mL and adjusted during the procedure as necessary. 27 Patients began collection B4 h after the completion of the plerixafor infusion. Patients continued to receive daily G-CSF and IV plerixafor each morning of apheresis for a maximum of four doses or until the collection goal was met. Patients were allowed to undergo additional apheresis collections beyond the fourth collection at the discretion of the treating physician; however, only four doses of plerixafor could be administered.
Patients were typically conditioned with melphalan 200 mg/m 2 , with dose reduction to 140 mg/m 2 for patients with reduced renal function or patients over 70 years. Post-transplant G-CSF was not routinely used for any of the patients. Engraftment kinetics were examined in the subgroup of patients who proceeded to a SCT. Neutrophil engraftment was defined as the neutrophil count X0.5 Â 10 9 /L for 3 days or X1.0 Â 10 9 /L for 1 day. Platelet engraftment was defined as platelet count X20 Â 10 9 /L without a transfusion for the preceding 7 days.
Statistical analysis
For primary end point, success was defined as collection of 3 Â 10 6 CD34 þ cells/kg after 2 days of apheresis. The largest success proportion where the proposed treatment regimen would be considered ineffective in this population was 60%, and the smallest success proportion supporting future studies in this patient population was 80%. This design required 36 evaluable patients, in whom at least 26 successes were required to conclude that further studies be recommended. This design has 91% power and a 9% Type I error rate.
RESULTS
Forty patients were accrued between December 2009 and October 2011, and 39 were eligible for analysis. The baseline characteristics of the patients as well as other myeloma-related details are provided in Table 1 . The patients had received a median of four cycles with a lenalidomide-based regimen, mostly lenalidomide and dexamethasone. Nearly a quarter of the patients received a bortezomib and lenalidomide combination. The majority of patients had remained on full-dose lenalidomide prior to proceeding with study registration and stem cell collection.
In terms of the primary end point, 38 (97%) of the patients achieved at least 3 Â 10 6 CD34 þ cells/kg, adequate to proceed to one SCT, within 2 days of apheresis ( Table 2 ). The median CD34 þ cells/kg after 1 day of collection was 3.9 Â 10 6 (range: 0.7-9.2) and after 2 days of collection was 6.99 Â 10 6 (range: 1.1-16.5). The median number of cells collected on each apheresis day is shown in Figure 1 . We then examined the time taken to reach 4 Â 10 6 and 8 Â 10 6 CD34 þ cells/kg, given that these are typically considered the ideal numbers required for 1 and 2 transplants, respectively. As shown in Figure 2 , 38 patients were able to reach the 4 Â 10 6 threshold after four apheresis sessions, and 25 of the patients in whom the target was to collect for more than one transplant, achieved 8 Â 10 6 target after four sessions. The sole patient who failed to reach the primary goal of 3 Â 10 6 was a 61-year-old male who had received four cycles of lenalidomide at 25 mg (with dexamethasone). The total CD34 þ cell yield for this patient, over the course of 3 days, was 1.42 Â 10 6 cells/kg. The kinetics of the peripheral blood CD34 þ cell counts for the entire cohort are shown in Figure 3 .
The IV administration was well tolerated with no grade 3 or higher adverse events (Table 3) . The most common grade 1 or 2 adverse events seen were gastrointestinal, namely nausea, diarrhea and abdominal pain or bloating. Grade 1 dizziness was reported in eight patients. Infusion site reactions were observed in one patient. We then performed additional analyses to identify factors potentially contributing to slower collection. Given that all but one patient achieved the primary goal of 3 Â 10 6 CD34 þ cells/kg in 2 days, we compared the baseline clinical and laboratory characteristics between patients achieving 6 Â 10 6 in 2 days (N ¼ 25) vs those who did not. Specifically, we examined if age, time from diagnosis to registration, lenalidomide dose at start of therapy and at end of therapy, days between stopping lenalidomide and start of mobilization, duration of lenalidomide therapy, and blood counts, serum creatinine, serum albumin, BM plasma cell percentage, plasma cell labeling index and beta2 microglobulin from study registration influenced the ability to collect stem cells. Presence of active myeloma, as reflected in a higher percentage of (BM) plasma cells, higher beta 2 microglobulin and higher plasma cell labeling index, was the only factor affecting the ability to mobilize and the rate of collection.
At the time of data analysis, 34 (87%) patients had received auto-SCT. The median time to ANC engraftment was 14 days (range: 11-21) and to platelet engraftment was 15.5 days (range: 12-38).
DISCUSSION
The results of the current trial highlights two aspects of plerixaforand G-CSF-based stem cell mobilization: the ability to administer the drug intravenously in a safe and effective manner and the ability of plerixafor-based mobilization to overcome the adverse impact of lenalidomide-based initial therapy. The current study represents the first trial specifically designed to evaluate the feasibility of i.v. administration of plerixafor for stem cell mobilization. The results of the current trial should be interpreted in the context of the previous trials evaluating the SQ administration. 16, 29 In the randomized trial comparing plerixafor and G-CSF with G-CSF alone in patients with myeloma undergoing PBSC mobilization, a similar treatment schedule and dosing was utilized. 16 The proportion of patients collecting 6 Â 10 6 CD34 þ cells/kg in 2 days in this study was 67% (26 of 39), similar to the 71.6% seen with the use of SQ plerixafor in the randomized trial. With respect to the minimal collection, 97% of the patients collected at least 3 Â 10 6 CD34 þ cells/kg, which is comparable to the 95.3% who collected at least 2 Â 10 6 CD34 þ cells/kg in four apheresis sessions in the randomized trial. However, the peripheral blood CD34 þ cell counts were lower with IV plerixafor than those seen in the plerixafor arm of the randomized trial. Overall, the results are comparable with what has been observed previously in this patient population with the use of SQ plerixafor. In terms of toxicity, the types of toxicity and the severity were comparable to the SQ administration, with gastrointestinal symptoms being the most common.
It is difficult to directly compare the results of the current study with those from the randomized trials, given that o5% of the patients in the plerixafor arm had received lenalidomide. We have previously shown that lenalidomide therapy can adversely affect the ability to mobilize stem cells in the context of G-CSF-based mobilization. 11 In that study, patients who had received lenalidomide therapy for induction had a significantly lower total CD34 þ cell yield, lower average daily CD34 þ cell and lower CD34 þ cell collection on first day, first 2 days and first 3 days and a greater number of collections compared with those receiving VAD (Vincristine, adriamycin and dexamethasone) or dexamethasone alone for induction therapy. Overall, 7% of patients failed mobilization and stem cell collection in the context of prior therapy with lenalidomide. The median CD34 þ cell collection in the lenalidomide-treated patients on days 1 and 2 of apheresis were 1.7 Â 10 6 CD34 þ cells/kg each, compared with 3.55 and 3.7 Â 10 6 CD34 þ cells/kg in the current trial, respectively. Other studies have also reported higher failure rates with G-CSF-based mobilization among lenalidomide-treated patients. Popat et al.
14 reported a mobilization failure (o2 Â 10 6 CD34 þ cells/kg) rate of 25% with G-CSF alone in patients who had previously received lenalidomide. In a case series, mobilization with G-CSF (10 mg/kg/day) alone or G-CSF (7.5 mg/ kg/day) plus GM-CSF (7.5 mg/kg/day) resulted in a failure rate of 43%. 13 In the series by Paripati et al., 12 45% of patients failed to reach the target of at least 2 Â 10 6 CD34 þ cells/kg with G-CSF (10 mg/kg/day). 12 Given the difficulty seen across multiple reports, several studies have looked at the utility of plerixafor in patients receiving initial therapy with lenalidomide. In a study examining the efficacy of plerixafor among lenalidomide-treated patients from across multiple studies, the overall median number of CD34 þ cells collected was 5.6 Â 10 6 /kg (range: 0.45 Â 10 6 -37.2 Â 10 6 /kg). 30 Of 60 patients, 52 (86.7%) had the minimum number of 2 Â 10 6 CD34 þ cells/kg collected and 38 (63.3%) had 5 Â 10 6 /kg CD34 þ cells collected. In the European compassionate use program, 35 patients previously treated with lenalidomide were given plerixafor plus G-CSF for remobilization. 31 The overall median number of CD34 þ cells collected was 3.4 Â 10 6 / kg (range: 1.1-14.8). The minimum required number of CD34 þ cells (X2.0 Â 10 6 /kg) was collected from 69% of patients in a median of 2 days. More recently, risk-adapted strategies for use of plerixafor have substantially reduced the failure rate in these patients.
Introduction of plerixafor clearly has increased the options for stem cell mobilization, enabling a substantial number of patients who otherwise would not have been able to proceed to SCT because of failure to collect adequate stem cells, to receive the benefit of this therapy. However, this has to be viewed in the context of the cost associated with the agent, which is substantial. The high cost of the drug has led to evaluation and development of several risk-adapted therapy models, all aimed at selectively using the drug in the patients who are most likely to fail with G-CSF alone. In addition, the duration of therapy with plerixafor is an important determinant of the cost, and randomized controlled trials have shown the maximum benefit during the initial 2-4 days of therapy, with diminishing returns beyond that time point.
In conclusion, i.v. administration is a safe and effective approach to plerixafor administration. The i.v. administration offers flexibility in patient scheduling with a schedule of early-morning infusion followed by apheresis later in the day. However, prospective randomized controlled trials will have to be performed for a more accurate comparison of the pros and cons of the two routes of administration. The use of plerixafor clearly allows for effective stem cell mobilization in patients previously treated with lenalidomide, an important finding given the common use of lenalidomide for initial therapy of myeloma.
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